Skip to search formSkip to main contentSkip to account menu

IMAB362

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ClaudiximabMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
16 Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant… 
Review
2019
Review
2019
Dawn of precision medicine on gastric cancer
BackgroundIn recent years, a better understanding of tumor biology and molecular features of gastric cancer has been reached. It… 
2018
2018
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
2018
2018
Characterization of zolbetuximab in pancreatic cancer models
ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon… 
Highly Cited
2016
Highly Cited
2016
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line…
LBA4001Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ… 
Review
2016
Review
2016
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer.
  • K. ShitaraA. Ohtsu
  • The Journal of the National Comprehensive Cancer…
  • 2016
  • Corpus ID: 21625705
In recent years, various new agents have been investigated for the treatment of advanced gastric cancer (AGC). The anti-HER2… 
2015
2015
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.
e15079 Background: IMAB362 is the first-in-class monoclonal antibody against the tight junction molecule claudin 18.2 (CLDN18.2… 
Highly Cited
2014
Highly Cited
2014
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
The majority of pancreatic neoplasms are characterized by a generally lethal progress within a short period of time after primary… 
2014
2014
636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY.
ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on… 
2013
2013
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
4080 Background: IMAB362 is a monoclonal antibody targeting isoform 2 of the tight junction component claudin 18 (CLDN18.2), a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)